SCHEMBL316306

SCHEMBL316306

Cc1nc2ncccc2o1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
NPC1 O15118 7/20 0.50
RAB9A P51151 6/20 0.50
SMN1; SMN2 Q16637 4/20 0.50
HPGD P15428 3/20 0.50
HSD17B10 Q99714 2/20 0.50
TP53 P04637 1/20 0.50
ALOX12 P18054 1/20 0.50
HAVCR2 Q8TDQ0 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
ALDH1A1 P00352 4/20 0.47
GAA P10253 2/20 0.47
MAPT P10636 2/20 0.47
FAAH O00519 9/20 0.46
DAGLA Q9Y4D2 5/20 0.44
CHRNA7 P36544 1/20 0.42
HTR3A P46098 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1427654 0.77 NPC1 (0.51) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3331943 0.75 NPC1 (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL2008234 0.75 NPC1 (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL10278988 0.75 NPC1 (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL221452 0.75 NPC1 (0.59) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL7537268 0.75 NPC1 (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL1427656 0.75 NPC1 (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL2414410 0.75 NPC1 (0.54) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL22221895 0.75 NPC1 (0.51) KDM4ENPC1RAB9ASMN1; SMN2HPGD
SCHEMBL10272992 0.75 FAAH (0.50) KDM4ENPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US claimed
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS ISTITUTO GIANNINA GASLINI (IT) 2023-07-06 US claimed
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE ISTITUTO ITALIANO DI TECHNOLOGIA (IT) 2023-03-07 US claimed
CN-111560026-A High-optical-stability cell membrane fluorescent marker and preparation method and application thereof 苏州大学 2020-08-21 CN claimed
US-20150291623-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2015-10-15 US claimed
US-20120295897-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2012-11-22 US claimed
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis FONDAZIONE INSTITUTO ITALIANO DI TECNOLOGIA (IT) 2025-12-09 US disclosed
US-11818932-B2 Organic light-emitting device SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-14 US disclosed
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF WUHAN TIANMA MICROELECTRONICS CO., LTD. (CN) 2023-11-09 US disclosed
US-11795163-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same CHECKMATE THERAPEUTICS INC. 2023-10-24 US disclosed
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates AC IMMUNE SA (CH) 2023-08-17 US disclosed
EP-4225006-A2 ORGANIC LIGHT-EMITTING DEVICE Samsung Display Co., Ltd. (KR) 2023-08-09 EP disclosed
EP-4219465-A2 PRMT5 INHIBITORS AND USES THEREOF Epizyme Inc (US) 2023-08-02 EP disclosed
EP-1362894-A2 Method for optical measurement of multi-stranded nucleic acid using cyanine dyes FUJI PHOTO FILM CO., LTD. (JP) 2003-11-19 EP disclosed
US-20030087928-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD., JAPAN 2003-05-08 US disclosed
US-20020099074-A1 Novel anilide compounds and drugs containing the same KOWA COMPANY, LTD.,JAPAN 2002-07-25 US disclosed
US-20020077487-A1 Modified carbocyanine dyes and their conjugates MOLECULAR PROBES, INC. 2002-06-20 US disclosed
US-20020064794-A1 Modified carbocyanine dyes and their conjugates MOLECULAR PROBES, INC. 2002-05-30 US disclosed
US-6362208-B1 ANTICHOLESTEROL AGENT KOWA COMPANY, LTD. (JP) 2002-03-26 US disclosed
EP-1020451-A1 NOVEL ANILIDE COMPOUNDS AND DRUGS CONTAINING THE SAME Kowa Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230255976-A1 Novel Compounds for the Treatment, Alleviation or Prevention of Disorders Associated with Tau Aggregates MAPT, MAP1LC3A, MAP1LC3B KDM4E 4066/4885NPC1 290/4885RAB9A 1905/4885
US-20020077487-A1 Modified carbocyanine dyes and their conjugates IK, CBR3, DRD5 KDM4E 2829/4885NPC1 2746/4885RAB9A 2413/4885
US-20230357188-A1 PHENANTHRENE ORGANIC COMPOUND AND USE THEREOF AHR, ORAI3, WNT3 KDM4E 3942/4885NPC1 2396/4885RAB9A 3127/4885
US-20030087928-A1 Novel anilide compounds and drugs containing the same ACAT1, ACAT2, LCAT KDM4E 450/4885NPC1 79/4885RAB9A 1626/4885
US-20230212157-A1 PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CYSTIC FIBROSIS CFTR, ABCC5, ABCC1 KDM4E 4688/4885NPC1 137/4885RAB9A 1996/4885
US-20020099074-A1 Novel anilide compounds and drugs containing the same SOAT1, SOAT2, LCAT KDM4E 579/4885NPC1 113/4885RAB9A 3004/4885
US-20150291623-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS TRPV3, TRPV1, TRPC3 KDM4E 4619/4885NPC1 790/4885RAB9A 1615/4885
US-12492193-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC1 KDM4E 4688/4885NPC1 137/4885RAB9A 1996/4885
US-11597723-B2 Pyrazole derivatives for the treatment of cystic fibrosis CFTR, ABCC5, ABCC3 KDM4E 4681/4885NPC1 132/4885RAB9A 1997/4885
US-20120295897-A1 SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS TRPV3, TRPC3, TRPV1 KDM4E 4646/4885NPC1 804/4885RAB9A 1619/4885
US-11795163-B2 Compound for inhibiting nicotinamide phosphoribosyltransferase and composition containing same NAMPT, NAPRT, NNT KDM4E 2598/4885NPC1 269/4885RAB9A 2946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.